Bladder and Gastric Metastases from Lung Adenocarcinoma Harboring Codon 13 KRAS Mutation: a Case Report with Unusual Clinical Outcome

Abstract

Aims and background

Gastric and bladder metastases are rare in non-small-cell lung cancer (NSCLC) and the differential diagnosis with primary tumors requires an in-depth examination. KRAS gene mutations are the main oncogenic driver of lung adenocarcinoma in Caucasian patients, occurring in 25%-30% of cases, but their prognostic and predictive role is complex and not fully clarified. KRAS mutations in lung adenocarcinoma are considered negatively predictive for epidermal growth factor receptor tyrosine kinase inhibitors therapy as well as for adjuvant chemotherapy. In this report, the authors describe a case of lung adenocarcinoma harboring a codon 13 KRAS mutation detected in all the biopsies performed in unusual metastatic sites during an atypical disease course.

Conclusions

Recently, a different prognostic significance of various KRAS mutations in lung adenocarcinoma has been suggested. Further studies on rare biomolecular alterations to identify subgroups of patients with different prognostic/predictive characteristics are needed.

Keywords

Bladder metastases Lung adenocarcinoma

Get full access to this article

View all access options for this article.

References

Xiao

G.Q.

, Chow

, Unger

P.D.

Metastatic tumors to the urinary bladder: clinicopathologic study of 11 cases. Int J Surg Pathol. 2012; 20(4): 342–348.

Rossi

, Marchioni

, Romagnani

Primary lung cancer presenting with gastrointestinal tract involvement: clinicopathologic and immunohistochemical features in a series of 18 consecutive cases. J Thorac Oncol. 2007; 2(2): 115–120.

Suda

, Tomizawa

, Mitsudomi

Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev. 2010; 29(1): 49–60.

Riely

G.J.

, Kris

M.G.

, Rosenbaum

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res. 2008; 14(18): 5731–5734.

Kim

H.R.

, Shim

H.S.

, Chung

J.H.

Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer. 2012; 118(3): 729–739.

Shepherd

F.A.

, Domerg

, Hainaut

Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol. 2013; 31(17): 2173–2181.

Metro

, Chiari

, Duranti

Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype. Lung Cancer. 2012; 78(1): 81–86.

Garassino

M.C.

, Marabese

, Rusconi

Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. Ann Oncol. 2011; 22(1): 235–237.

Cserepes

, Ostoros

, Lohinai

Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy. Eur J Cancer. 2014; 50(10): 1819–1828.

10.

Metro

, Chiari

, Bennati

Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status. Clin Lung Cancer. 2014; 15(1): 86–92.

11.

De Roock

, Jonker

D.J.

, Di Nicolantonio

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010; 304(16): 1812–1820.

12.

Mao

, Huang

Y.F.

, Yang

Z.Y.

, Zheng

D.Y.

, Chen

J.Z.

, Tang

J.L.

KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis. Cancer. 2013; 119(4): 714–721.